Clinical Trial Update: MK-7075 (Miransertib) in Proteus Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 study of Miransertib (MK-7075) for Proteus Syndrome is currently recruiting, sponsored by the National Human Genome Research Institute.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proteus Syndrome

Drugs mentioned

• Miransertib (MK-7075) (miransertib)

Snippet

Sponsor: National Human Genome Research Institute (NHGRI) | Conditions: Proteus Syndrome | Phase 2 | Status: RECRUITING